Get started
Author

B. Glimelius

Improved Survival of Patients With Cancers of the Colon and Rectum?2
1988 · P. Enblad, H.-O. Adami, et al. · JNCI Journal of the National Cancer Institute · 64
Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?
2008 · Å. Berglund, B. Cedermark, et al. · Annals of Oncology · 51
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab
2013 · F. Sclafani, A. Roy, et al. · Annals of Oncology · 33
Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion
2008 · H. Mahteme, I. Wallin, et al. · European Journal of Clinical Pharmacology · 31
PDF
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial
2015 · F. Sclafani, I. Chau, et al. · Annals of Oncology · 27
PDF
Preoperative treatment selection in rectal cancer: A population-based cohort study
2014 · A.H. Elliot, A. Martling, et al. · European Journal of Surgical Oncology · 22
Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
2007 · B. Glimelius · Annals of Oncology · 9
Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC)
2017 · F. Sclafani, G. Brown, et al. · Annals of Oncology · 4
PDF
Updated results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer
2017 · T. Iveson, R. Kerr, et al. · Annals of Oncology · 3
Molecular classification of microsatellite-instable colorectal cancers reveals distinct predictors of immunotherapy response
2025 · C. Lin, T. Luo, et al. · ESMO Gastrointestinal Oncology · 2
PDF
KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial
2016 · F. Sclafani, I. Chau, et al. · Annals of Oncology · 1
847P Molecular-clinical characteristics and treatment outcome for metastatic colorectal neuroendocrine carcinomas and adenocarcinomas: A comparison of two population-based prospective cohorts
2025 · S. Morken, S.W. Langer, et al. · Annals of Oncology
Safety and efficacy of S-1-based treatment in colorectal cancer patients who switched to S-1 after development of cardiotoxicity on fluoropyrimidine-based adjuvant or neoadjuvant treatment
2025 · S Kinos, E Osterlund, et al. · European Heart Journal Supplements
60P No liver metastases vs liver metastases in metastatic colorectal cancer (mCRC)
2025 · E. Osterlund, S. Aho, et al. · Annals of Oncology
PDF
235P Outcomes of a rectal cancer population treated with capecitabine-based chemoradiation compared with a cohort switched to S-1 for cardiotoxicity
2025 · P.J. Osterlund, K.I. Lehtomaki, et al. · Annals of Oncology
PDF
114P Molecular alterations in a population-based metastatic colorectal cancer (mCRC) cohort
2024 · E. Osterlund, K. Hammarström, et al. · Annals of Oncology
PDF
65P Costs and resource utilization in the curative and palliative treatment phases of metastatic colorectal cancer: Patient-level data analysis of the Finnish RAXO study
2024 · P.J. Osterlund, J. Kontiainen, et al. · Annals of Oncology
410P Prognostic value of baseline ECOG performance status, frailty phenotype, and geriatric screening tools (G8 and VES-13) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study
2022 · G. Liposits, J. Ryg, et al. · Annals of Oncology
PDF
345P The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study
2022 · G. Liposits, H. Skuladottir, et al. · Annals of Oncology
PDF
432P Determinants of pre-surgical treatment in primary rectal cancer: A population-based study
2022 · I. Imam, K. Hammarström, et al. · Annals of Oncology
Neutrophils Predicting Tumor Local Control After Chemoradiation Therapy in Locally Advanced Pancreatic Carcinoma in the LAP 07 Trial
2017 · A. Schernberg, D. Vernerey, et al. · International Journal of Radiation Oncology*Biology*Physics
Age Dependent Increase in Median and Long-Term Survival in 29 628 Metastatic Colorectal Cancer (MCRC) Scandinavian Patients During the Past Two Decades
2012 · C. Qvortrup, M. Cvancarova, et al. · Annals of Oncology
PDF
[Cytostatic therapy in cancer--a SBU report].
2001 · B Glimelius, P Nygren, et al. · PubMed
[Possible effect of administration methods on pharmacological action. Study of cytostatic therapy in advanced cancer].
1995 · P A Larsson, G Carlsson, et al. · PubMed
Works count: 24
Citation count: 247
H-index: 7
I10-index: 6
Year
Topic
Type